Seoul Viosys서울바이오시스
092190 · KOSDAQ · ₩092190 · 서울바이오시스
₩8,580▲ ₩1,980 (30.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 17.8% | 14.5% | 14.7% | 4.6% | 4.3% | 16.6% |
| Operating margin | 4.3% | 0.0% | 0.5% | −14.5% | −14.2% | 4.6% |
| Net margin | 2.1% | −2.0% | 1.0% | −17.6% | −19.7% | 0.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +6.0% | +9.2% | +38.7% | +14.9% | −10.2% | — |
| Operating income growth | +15,335.6% | −93.5% | +104.8% | −17.4% | −378.9% | — |
| Net income growth | +209.2% | −317.0% | +108.0% | −2.9% | −2,044.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 19.0% | −26.5% | 25.1% | −183.1% | −70.7% | 2.7% |
| Return on assets | 3.5% | −1.8% | 2.4% | −13.7% | −12.2% | 2.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 280.3% | 322.5% | 494.2% | 689.1% | 351.3% | 201.4% |
| Net debt to equity | 110.7% | 112.7% | 228.1% | 340.3% | 189.1% | 119.8% |
| Current ratio | 58.7% | 53.9% | 52.9% | 45.3% | 73.3% | 81.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Seoul Viosys / 서울바이오시스 / 092190 / KRX:092190
Source: KRX statistical information